This inhibition disrupts cytokine–cytokine receptor interactions, particularly by inactivating Ccl2 and Cx3cl1, which suggests that Stattic effectively alleviates L-AKI symptoms by suppressing the chemokine-dependent JAK-STAT signaling pathway and modulating the activity of innate immune cells, particularly macrophages. This evidence concerns the gene CX3CL1 and acute kidney injury.